NCT04351516

Test and Treat COVID 65plus+

Randomized Controlled Trial of Hydroxychloroquine Versus Placebo in Early Ambulatory Diagnosis and Treatment of Elderly COVID19 Patients

• Status: Withdrawn
• Phase: Phase 2 / Phase 3
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: University Hospital Tuebingen · Academic / Other
• Sex: All
• Age: 65 Years
• Healthy volunteers: Not accepted

Summary

Patients over equal or older than 65 yearswill be treated with a hydroxychloroquine versus placebo reduced loading dose of 600mg on the first day followed with 400mg/day divided in 2x200mg for 6 more days resulting in a total duration of therapy of 7 days. Measurement of Hydroxychloroquine-levels will be performed on day 7, . A follow-up by video or telephone conference will be performed to observe drug intake and collect adverse events during treatment phase on a daily base on working days and once during the weekend (i.e. 6 out of 7 days). After treatment phase follow-up by telephone calls will be done on day 10, 30, 60 (+/- 2 days).

Conditions

• SARS-CoV 2
• COVID-19

Interventions

Type	Name	Description
DRUG	Hydroxychloroquine	dose of 600mg on the first day followed with 400mg/day divided in 2x200mg for 6 more days
OTHER	Placebo	Placebo: Film Coated Tablette

Timeline

• Start date: 2020-04-21
• Primary completion: 2020-12-31
• Completion: 2021-05-01
• First posted: 2020-04-17
• Last updated: 2021-01-15

Locations

2 sites across 1 country: Germany